文献速递乳房整形与再造显微修复重建

乳腺癌类型、分期与治疗对即刻游离皮瓣乳房再造血管并发症的影响

The Impact of Breast Cancer Type, Staging, and Treatment on Vascular Complications of Immediate Free-Flap Breast Reconstruction.
PubMed 文献 · Ann Plast Surg · 2023-01-18

这项回顾性研究分析了2009至2018年接受自体游离皮瓣乳房再造的患者,评估乳腺癌分期、激素受体状态及新辅助治疗对术中术后血管问题及皮瓣丢失的影响。结果显示新辅助激素治疗与术中血管问题风险升高相关(OR 1.059,P=0.0441),新辅助曲妥珠单抗与术后血管问题风险降低相关(OR 0.941,P=0.018),而分期、受体类型、化疗及放疗对血管并发症无影响。

要点

  • 新辅助激素治疗与术中血管问题风险升高相关(OR 1.059,P=0.0441)。
  • 新辅助曲妥珠单抗与术后血管问题风险降低相关(OR 0.941,P=0.018)。
  • 乳腺癌分期、受体类型、化疗及放疗对血管并发症无影响。

核心结论

  • 自体游离皮瓣乳房再造对所有分期和类型的乳腺癌患者是可靠的重建选择。
  • 接受新辅助激素治疗的患者术中微血管受损风险可能增加。
  • 曲妥珠单抗可能对术后微血管受损有保护作用。
  • 患者不应因癌症分期较高而害怕血管受损,可追求期望的重建方案。

研究设计与样本

  • 回顾性研究,纳入2009年至2018年接受自体游离皮瓣乳房再造的患者。
  • 收集乳腺癌分期、癌症类型、激素受体状态、治疗及人口学数据。
  • 分析术中血管问题、术后血管问题及皮瓣丢失。
  • 采用单因素分析和固定效应模型关联乳腺癌特征与结局。

主要发现

  • 新辅助激素治疗与术中血管问题风险升高相关(OR 1.059,P=0.0441)。
  • 新辅助曲妥珠单抗与术后血管问题风险降低相关(OR 0.941,P=0.018)。
  • 乳腺癌分期、体细胞基因突变、受体类型、新辅助化疗及新辅助放疗对ABR的任何血管并发症均无影响。

临床怎么用

  • 作者认为自体游离皮瓣乳房再造对所有分期和类型的乳腺癌患者是可靠的重建选择。
  • 作者指出接受新辅助激素治疗的患者术中微血管受损风险可能增加。
  • 作者指出曲妥珠单抗可能对术后微血管受损有保护作用。
  • 作者认为患者不应因癌症分期较高而害怕血管受损,可追求期望的重建方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with advanced cancer staging have a greater risk of developing venous thromboembolism than noncancer patients. The impact of breast cancer stage and treatment on outcomes after autologous free-flap breast reconstruction (ABR) is not well-established. The objective of this retrospective study is to determine the impact of breast cancer characteristics, such as cancer stage, hormone receptor status, and neoadjuvant treatments, on vascular complications of ABR. METHODS: A retrospective review was conducted examining patients who underwent ABR from 2009 to 2018. Breast cancer stage, cancer types, hormone receptor status, and treatments were collected in addition to demographic data. Intraoperative vascular concerns, postoperative vascular concerns, and flap loss were analyzed. Univariate analysis and fixed-effects models were used to associate breast cancer characteristics with outcomes. RESULTS: Neoadjuvant hormone therapy was associated with increased risk for intraoperative vascular concern (odds ratio, 1.059 [ P = 0.0441]). Neoadjuvant trastuzumab was associated with decreased risk of postoperative vascular concern (odds ratio, 0.941 [ P = 0.018]). Breast cancer stage, somatic genetic mutation, receptor types, neoadjuvant chemotherapy, and neoadjuvant radiation had no effect on any vascular complications of ABR. CONCLUSION: Autologous free-flap breast reconstruction is a reliable reconstructive option for patients with all stages and types of breast cancer. There is potentially increased risk of intraoperative microvascular compromise in patients who have neoadjuvant hormone therapy. Trastuzumab is potentially protective against postoperative microvascular compromise. Patients should feel confident that, despite higher stage cancer, they can pursue their desired reconstructive option without fear of vascular compromise.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Talwar AA, Mazzaferro D, Morris MP, et al. The Impact of Breast Cancer Type, Staging, and Treatment on Vascular Complications of Immediate Free-Flap Breast Reconstruction. Ann Plast Surg. 2023. PMID: 36752516. doi:10.1097/SAP.0000000000003411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。